Crescent Biopharma
CBIO
48 hedge funds and large institutions have $132M invested in Crescent Biopharma in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 7 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
2% less capital invested
Capital invested by funds: $135M → $132M (-$2.92M)
4% less funds holding
Funds holding: 50 → 48 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$402K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$396K |
| 3 |
State Street
Boston,
Massachusetts
|
+$213K |
| 4 |
Renaissance Technologies
New York
|
+$149K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$126K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$639K |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$400K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$204K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$190K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$187K |
CBIO Hedge Fund Activity: Q3 2016 in Review
48 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2016, worth a combined $132M — down 2.2% from $135M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CBIO and 5 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 15 added.
The largest buyer was Wellington Management Group, adding an estimated $402K. The largest seller was Goldman Sachs, exiting entirely with an estimated $639K sold.
- 48 institutional investors held Crescent Biopharma (CBIO) as of Q3 2016, down from 50 in Q2 2016.
- Funds reported $132M of Crescent Biopharma stock for Q3 2016, down 2.2% quarter-over-quarter.
- 5 funds opened new Crescent Biopharma positions in Q3 2016 and 7 closed out, a net change of -2 holders.
- The largest Crescent Biopharma buyer in Q3 2016 was Wellington Management Group, an estimated $402K added.
- The largest Crescent Biopharma seller in Q3 2016 was Goldman Sachs, an estimated $639K sold.
Based on aggregated 13F filings for Q3 2016.